Decrease in GPSM2 mediated by the natural product luteolin contributes to colon adenocarcinoma treatment and increases the sensitivity to fluorouracil

Affiliations

• 1 The First Laboratory of Cancer Institute, The First Hospital of China Medical University, Shenyang, China; Department of Oncology, The Fifth Affiliated Hospital of Guangxi Medical University & The First People's Hospital of Nanning, Nanning, Guangxi, China.
• 2 Department of Laboratory Medicine, Shengjing Hospital of China Medical University, No. 36, San Hao Street, Shenyang, Liaoning 110004, China; Liaoning Clinical Research Center for Laboratory Medicine, Shenyang, China.
• 3 Department of Respiratory Medicine, The Fifth Affiliated Hospital of Guangxi Medical University & The First People's Hospital of Nanning, Nanning, Guangxi, China.
• 4 The First Laboratory of Cancer Institute, The First Hospital of China Medical University, Shenyang, China.
• 5 The First Hospital of China Medical University, Shenyang, China.
• 6 Liaoning University Of Traditional Chinese Medicine, Shenyang, China.
• 7 The First Clinical College, China Medical University, Shenyang, China.
• 8 Department of Medical Oncology, Cancer Hospital of China Medical University, China.
• 9 The First Laboratory of Cancer Institute, The First Hospital of China Medical University, Shenyang, China; Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
• 10 Department of Laboratory Animal Science, China Medical University, Shenyang, China.
• 11 The First Hospital of China Medical University, Shenyang, China. Electronic address: cmujixu@163.com.
• 12 The First Laboratory of Cancer Institute, The First Hospital of China Medical University, Shenyang, China. Electronic address: zhangyecmu@163.com.